Introduction and hypothesis To determine if abobotulinumtoxin A (AboBTXA) is an effective treatment for interstitial cystitis/ bladder pain syndrome (IC/BPS). Methods We performed a double-blind study of 54 women with severe, refractory IC from three referral centres whom we randomly allocated to treatment with hydrodistension + injection of normal saline or to hydrodistension + injection with AboBTXA. The O'Leary-Sant questionnaire consists of problem (OLS-PI) and symptom (OLS-PI) index scores, and bladder diary data were compared between AboBTXA and control patients at baseline and at 3 months of follow-up.
Introduction
Preliminary evidence suggested that abobotulinum toxin A (AboBTXA) may be effective for treating interstitial cystitis/ bladder pain syndrome (IC/BPS) when injected into the bladder wall [1] [2] [3] [4] [5] .In 2005, El-Bahnasy et al reported results of a prospective study of 36 women with refractory IC/PBS randomised to have either bacille Calmette-Guerin (BCG) weekly for 5 weeks or injection of 300 U of onabotulinumtoxin (Botox®). Significant improvement was noted in the domains of daytime frequency, nocturia, pelvic pain, urgency and dysuria among women randomised to treatment with AboBTXA. No significant difference in complications between groups, in particular voiding dysfunction, was noted [6] . Several mechanisms for the possible effectiveness of AboBTXA in treating bladder pain have been suggested. AboBTXA may inhibit the release of neuropeptides, such as substance P, calcitonin-gene-related peptide and glutamate, which are all involved in pain transmission from either dorsal root ganglion neurones, sensory afferent nerves and/ or urothelial cells. It is speculated that this could happen in a similar manner to that in which AboBTXA inhibits acetylcholine release from motor nerve terminals by cleavage of snap proteins. The aim of this prospective, randomised, double blind study was to determine whether hydrodistension + AboBTXA injection into the bladder wall could significantly improve symptoms for women with chronic refractory IC/BPS when compared with treatment with hydrodistension + saline injection
Materials and methods
From January 2004 until February 2009, 54 female patients with longstanding refractory IC/PBS were recruited from urogynaecology clinics at three centres. They were followed up for at least 2 years. Study participants all met the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) [7] criteria in use at that time, with the majority having had multiple prior therapies. Being refractory was defined as having failed two or more recognised treatments. Study participants were >18 years of age. Exclusion criteria included a known history of recurrent urinary tract infection (UTI), current pregnancy, bladder malignancy, steroid use, and voiding difficulty. All patients completed a 3-day bladder diary and baseline questionnaires. The primary outcome measure was the O'Leary-Sant questionnaire score (OLS), which is composed of two parts: the OLS Symptom Index (OLS-SI) and the OLS Problem Index (OLS-PI). The latter is similar to a bother score: How much has this been a problem for you? The four questions relate to daytime frequency, nocturia, need to urinate with little warning, and question 4 that addresses bladder pain. Each question in the OLS-SI is scored 0 for not at all to 5 for usually or almost always, with a maximum score of 20. Questions in the OLS-PI are scored 0 for no problem to 4 for big problem, with a maximum score of 16. The secondary outcome measures were frequency and nocturia as measured by bladder diary, and complications such as voiding difficulty. Individuals were randomised to receive, under general anaesthetic, either a 4-min hydrodistension with injection of 30 ml normal saline into the bladder wall or with injection of 500 U AboBTXA (Dysport®) diluted in 30 ml normal saline. Both were injected suburothelially in 1-ml aliquots through a 30-cm, 23-gauge Bard needle at 30 sites, sparing the trigone and avoiding ureters. A bladder biopsy was obtained if not already available. Perioperative antibiotic prophylaxis was utilised. Urodynamic studies were performed upon recruitment, if not previously available. A free urinary flow rate with postvoid residual was performed at 1 week posttreatment and repeated if elevated.
Patients and treating doctors were blinded to initial treatment allocation. Drugs were prepared in the hospital pharmacy according to a series of three separate computer-generated randomisation numbers for each centre provided by the mathematics department and were held confidentially by pharmacy. Deidentified syringes were delivered to theatre. One ampoule of Dysport® 500 U is variably estimated to be equivalent to approximately 2 to 2.5 ampoules of Botox® 100 U (Allergan, Highlands Ranch, CO, USA) [8, 9] . Four patients from one centre were randomised and initially received only 200 U of AboBTXA (assumed equivalent to 100 U Botox®). Patients with no improvement after initial treatment had access at a minimum of 3 months after initial treatment to AboBTXA treatment if they wished, as indicated in the flow chart (Fig. 1 ). Patients and doctors remained blinded to the original treatment allocation. Approval for the study was obtained from the Research and Ethics Committees of all three hospitals.
Statistical methods
A formal power calculation was not performed prior to the study. The sample size of 50 was determined as being confident of detecting a 15 % difference in total O'Leary-Sant score between AboBTXA and control groups, if present. This was based on the one available randomised study available at the time, which involved 36 refractory patients. In this study, a difference of 16 % in global scores was demonstrated when OnaBTXA was compared with BCG injection at 4 weeks and had an 88 % excellent response rate [6] . Repeated measures analysis of variance (ANOVA) was used to test whether BTXA patients showed improvement in OLS scores, and the significance of mean differences at 3 months for each group was determined using paired t test and 95 % confidence intervals (CI). SPSS (V19) was used for analysis, and statistical significance was set at 0.05. Repeated-measures ANOVA was used to check for confounding factors. Measurements continued beyond 3 months; however, further randomised statistical comparisons were not possible, as the majority of patients chose to take up the offer of active AboBTXA injection at or beyond 3 months. Whether individual patients received a benefit was also assessed using a Reliable Change Index (RCI) to identify those with a statistically significant reduction in scores [10, 11] . A clinically significant improvement was defined as a reduction in baseline score ≥50 %. This analysis examines whether an individual had a statistically significant score change. An interim analysis was performed after enrolment of 20 patients to exclude adverse effects after one individual reported a marked increase in pain and voiding difficulty.
Results
Fifty-four patients were recruited: one was excluded prior to randomisation due to a diagnosis of bladder cancer. Mean age was 54 years for the AboBTXA group and 53 years for the control group; mean parity was two for both groups. There was also no difference in body mass index (BMI), with a mean of 27.5 for the AboBTXA group and 26.6 for the control group. This was a refractory group of IC patients; for example, patients who went on to have AboBTXA treatment had an average of seven prior treatments for IC/BPS [standard deviation (SD) 4.6]; controls had an average of four prior treatments. These included but were not limited to hydrodistension (100 % vs 88 %), bladder diathermy (25 % vs 50 %), bladder instillations (92 % vs 75 %), tricyclic antidepressants (75 % vs 50 %), Elmiron (75 % vs 50 %), and gabapentin or pregabalin (58 % vs 25 %) for the AboBTXA and control groups, respectively. In addition, average symptom duration for the AboBTXA and control groups Fig. 1 Treatment protocol was 16 years (SD 9.4) and 11 years (SD 4.1), respectively. Overall, mean maximum bladder capacity under anaesthesia was 491 ml (SD 243). Patients reported multiple other pain syndromes, but treatment allocation and OLS scores were not affected by the presence of these comorbidities.
The initial diary data analysis excluded two AboBTXA patients who did not have a complete bladder diary. Overall, the average number of voids per day was 13 and by night three. Mean maximum functional bladder capacity was 238 ml, and mean bladder capacity was 119 ml. Initial urodynamic test results were available for all women. Baseline urodynamic data for the two populations did not differ significantly; postvoid residual was not elevated, with a mean of 18 ml.
First sensation occurred at a mean of 97 ml and cystometric capacity at a mean of 178 ml. There were three patients with a detrusor pressure rise >15 cm water at capacity; no patient showed a systolic contraction pattern. Mean postvoid residual urine volume 1 week after initial treatment was 27ml for the control group and 69 ml for the AboBTXA group [not significant (NS); p =0.125). Two AboBTXA patients recorded a residual volume >200 ml, which persisted for 4 weeks in one of them.
OLS-PI and OLS-SI scores showed significant improvement for patients in both control and AboBTXA patients at 6 weeks and 3 months. OLS-PI showed a significantly greater improvement at 3 months in the AboBTXA group (p =0.04). A total of 12 patients had proven UTI detected and treated at some time after cystoscopy and injection-five controls and seven in the AboBTXA group-despite baseline negative urine culture and perioperative antibiotic prophylaxis. The presence of UTI was noted to be a confounding factor. If analysis was performed without UTI patients, as shown in Tables 1 and 2 , there was an overall improvement in the AboBTXA group in all measurements, including total OLS score (p =0.02), OLS-SI (p =0.008), OLS-PI (p =0.08) and question 4 of the OLS-PI addressing the problem of bladder pain (p =0.02).
Only two control group patients and five in the AboBTXA group had >50 % reduction in OLS score. Overall, the AboBTXA group had a 20 % greater improvement than the control group, but this was not significant (p = 0.10). Excluding patients with UTI led to significantly better response in the AboBTXA group (5/17, 29 %) compared with the control group (0/19, 0 %); p = 0.02, Fisher's exact test). Thirty nine patients had cold-cup bladder biopsy results available. Histology was considered abnormal if there was denudation of surface mucosa or inflammatory macrophage infiltrate in the urothelium and/or detrusor layer, although detrusor muscle was not always present in the specimen [12] . Detrusor mastocytosis was not measured. There was no difference in primary outcome measures among the 28 of 39 patients who showed abnormal biopsy results compared with those who did not.
Twenty one of the 27 (78 %) control patients requested AboBTXA treatment at or after 3 months, compared with 16 of the 26 (62 %) of initial AboBTXA patients; this was not a significant difference (p = 0.16). Patients and doctors remained blinded to their original allocation. Since then, nine women (24 %) have requested ongoing treatment. Among these women, study follow-up at the time of writing ranged from 0.5 to 72 months (mean 9.1; SD 13.5). These nine patients comprised seven of the 27 (26 %) original controls and two of the 26 (8 %) in the original AboBTXA group; however, this comparison did not reach significance (p = 0.08). One patient, who remained blinded, reported an initial treatment benefit with AboBTXA but failure following a second treatment. None of these nine patients had UTI identified. There was no statistically significant difference in results between the three participating hospitals (p =0.45). When benefit from one or multiple AboBTXA treatments occurred, the benefit varied from 7 to 57 months.
Discussion
In this study, intravesically administered injection of AboBTXA was not associated with overall improvement in total OLS score in women with refractory IC/BPS at 3 months, albeit an improvement was seen in the OLS-PI. However, when a statistical analysis of changes in patient scores was employed, some benefit was observed on the order of 20 % in OLS score in the AboBTXA compared with the control group, which rose to 29 % after UTI was excluded.
The randomised study by Kuo et al reported benefit at 3 months using both a visual analogue scale (VAS) for pain and the OLS questionnaire [13] . It is of interest that the same group recently reported no benefit from OnaBTXA in a group of patients with ulcerated IC, which is in agreement with the minimal overall benefit seen in this study [14] . El-Bahnasy [6] demonstrated benefit using a VAS, and Davies et al found no benefit in a study of 13 patients with doses of OnaBTXA between 100 and 300 U; three of their patients had urinary retention and pain exacerbation [15] . In El-Bahnasy's study, there was an unusually high and prolonged overall response rate to treatment, with 69 % and 88 % of those receiving BCG and OnaBTXA, respectively, reporting excellent response at nearly 2 years [6] . It should be noted that this high response rate to intravesically administered BCG treatment is far greater than the 11 % response for BCG treatment noted by Sairanen [16] , so perhaps the study population in El-Bahnassy's trial responded favourably to all treatment modalities. Patients recruited for the studies by El-Bahnassy and Kuo were required to have had symptoms for at least 6 months [6, 13] . Our study recruited a much more refractory group, with very long symptom duration, multiple failed treatments, mean maximum cystometric capacity of 178 ml and often abnormal bladder biopsy, which corresponds to patients in the ulcer group in Lee et al., who also responded poorly [14] .
UTI, diagnosed using traditional Kass criteria, was common, with no difference between the AboBTXA and control groups. The common occurrence of UTI has been noted elsewhere [17] . Furthermore, antibiotic prophylaxis is not always effective in preventing UTI during follow-up. These patients were not excluded from analysis, as UTIs occurred postrandomisation and posttreatment. It is difficult to speculate upon the reason for the apparent impact of UTI on response to treatment. Control patients with UTI showed greater improvement in scores than did those in the AboBTXA group, which confounded the results. Hence, when the analysis was performed excluding UTI patients, there was significantly greater improvement in OLS scores for the AboBTXA group. This suggests that there may be a role for infection in the pathogenesis or response to treatment in this group of patients.
This study was pragmatic in design, and hydrodistension was offered to both groups. This same approach was utilised by other centres [13] and was required by all institutional ethics committees involved in our study. Hydrodistension has previously been demonstrated to have an independent beneficial effect over a 3-month period, with concomitant reduced secretion of nerve growth factor [18] . However, hydrodistension treatment in both groups did not reduce our ability to detect benefit due to AboBTXA treatment alone, as no benefit was noted among the hydrodistension + saline injection treatment group.
A weakness of this study is the lack of formal power calculation, as at the commencement of the study, limited data was available, which consisted of the El-Bahnasy paper that showed an 88 % excellent response rate to BTXA [6] . Our study is likely to be underpowered for >50 % improvement. Indeed, recruitment time of this refractory group of IC/BPS patients was very long, even with this modest sample size of 50. However, the refractory nature of the condition was thought to be ethically justifiable in order to balance the cost and potential morbidity, such as urinary retention, of using AboBTXA.
The low incidence of voiding difficulty in this study compares favourably and contrasts with the 42 % incidence of voiding difficulty reported after 500 U AboBTXA was used for refractory idiopathic detrusor overactivity [19] . In our study, residual urine volumes were significantly raised in the AboBTXA group compared with the control group; however, only one patient had worsening pain and prolonged voiding difficulty over a 4-week period. This was despite the frequent finding of reduced flow rates on the pretreatment assessment. Dosage is unlikely to have been an issue, as previous studies demonstrated benefit using widely differing dosages.
Nine (24 %) patients requested a second (seven of the original control group) or third (two of the original AboBTXA group) ongoing treatment over 2 years following their initial randomisation treatment. As the drug was provided free of charge, this does suggest some benefit for this subset of patients. AboBTXA may be an effective treatment for a small minority of refractory patients. As women with refractory IC/BPS remain among the most difficult to treat, it could be argued that any safe therapy with even limited effectiveness is worth consideration.
Conclusion
For chronic refractory IC/BPS patients, there was no overall improvement in mean OLS score after injection of AboBTXA + hydrodistension versus saline injection + hydrodistension. The subgroup with no UTI had significant benefit in all OLS scores. This study found that intravesical injection of AboBTXA is an effective treatment in halving OLS scores for a small minority of women with refractory IC/BPS.
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